To assess how a patient with pulmonary arterial hypertension (PAH) is faring on therapy, look at the right heart, said Anjali ...

A new study published in The New England Journal of Medicine showed that for high-risk patients with pulmonary arterial ...

In addition to its health impact on patients, PAH leads to high payer-paid medical and pharmacy costs, as well as high out-of-pocket costs. 6 According to a study of commercial insurance and Medicare ...

Advanced Treatments Create New Prospects for Patients and Their Healthcare Providers New FDA-approved medical treatments can be transformative for patients and families, often providing them with more ...

The allowed claims in this patent encompass a novel dosing regimen of 200 ppm to 320 ppm gNO for 10 to 45 minutes, 2 to 5 times per day, to provide a nitric oxide-load (NO load) of 300 ppm-hrs to 900 ...

Key points include access to medicines in medicare is reduced as the IRA is implemented; fewer drugs are covered on Medicare ...

cardiovascular conditions such as pulmonary hypertension and right ventricular dysfunction, and higher mortality. Infants with FS measurements over 9 mm had a greater than 90 percent mortality rate.

Q1 2025 Earnings Call Transcript April 15, 2025 Johnson & Johnson beats earnings expectations. Reported EPS is $2.77, ...

“While our findings suggest a substantial role for PADN in treatment protocols, continuous research is crucial to fully understand its broader implications and long-term benefits.” The study, ...

Death is 'a reality we must face', wrote Pope Francis in a homily released during his hospitalization at Gemelli. 'It is a ...

Obe-cel is under regulatory review in both the EU and the U.K., and the Company expects to receive notification of approval status from the Medicines and Healthcare products Regulatory Agency (MHRA) ...